Seer Inc(SEER) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:34 PM ET (Korea 10/31 05:34)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.22 | Insider Own | 33.39% | Shs Outstand | 55.3M | Perf Week | -14.72% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | 3.95% | Insider Trans | -0.14% | Shs Float | 36.9M | Perf Month | -23.64% |
| Enterprise Value | -0.04B | PEG | - | EPS next Q | -0.26 | Inst Own | 23.28% | Short Float | 0.26% | Perf Quarter | -25% |
| Income | -0.07B | P/S | 6.6 | EPS this Y | 14.06% | Inst Trans | -0.33% | Short Ratio | 0.33 | Perf Half Y | -17.24% |
| Sales | 0.01B | P/B | 0.41 | EPS next 5Y | 12.08% | ROA | -23.47% | Short Interest | 0.09M | Perf YTD | -8.2% |
| Book/sh | 4.08 | P/C | 0.61 | EPS past 3/5Y | 4.89% -18.95% | ROE | -26.45% | 52W High | -29.26% ($2.38) | Perf Year | -24.66% |
| Cash/sh | 2.76 | P/FCF | - | Sales past 3/5Y | 3.15% 89.71% | ROIC | -27.7% | 52W Low | 8.39% ($1.55) | Perf 3Y | -0.59% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 12.29% | Gross Margin | 47.22% | Volatility(W/M) | 7.8% 5.18% | Perf 5Y | -95.45% |
| Dividend TTM | - | EV/Sales | -2.66 | Sales Y/Y TTM | -13.23% | Oper. Margin | -503.63% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.06 | EPS Q/Q | 8.4% | Profit Margin | -482.39% | RSI (14) | 27.37 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.74 | Sales Q/Q | -23.43% | SMA20 | -17.99% ($2.05) | Beta | 1.47 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/11/10 | SMA50 | -16.23% ($2.01) | Rel Volume | 1.79 | Prev Close | $1.94 |
| Employees | 124 | LT Debt/Eq | 0.09 | EPS/Sales Surpr. | -14.81% -12.62% | SMA200 | -12.53% ($1.92) | Avg Volume(3M) | 0.29M | Price | $1.68 |
| IPO | 2020/12/4 | Option/Short | Yes/Yes | Trades | 1671 | Volume | 516,545 | Change | -13.4% |
🧬 A US biotech company that develops and supplies mass spectrometry-based proteomics analysis platforms. Founded in 2017, it operates the Proteograph product line, which leverages nanoparticle technology, along with its own analytical service centers, and serves research institutions, pharmaceutical companies, and contract research organizations as its main customers.
Over the past 1 year, on the lower side
29% below its 1-year high.
Traded more than usual. That is 179% of its average volume.
Next earnings report: November 10
10 days to go.
SEER has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +14.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $660. Peers typically go for $1,010.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 23.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #367 of 597 in the industry
Based on market cap of $93M.
FAQ
What kind of company is SEER?
SEER belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SEER?
The market cap of SEER is approximately $93M, ranking 4,503 within its sector.
What is the 52-week high and low for SEER?
SEER has recorded a 52-week high of $2.38 and a low of $1.55.
